Privium Fund Management B.V. Biogen Inc. Transaction History

Privium Fund Management B.V.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$190.52 - $236.72 $30,483 - $37,875	-160 Reduced 2.23%	7,000 $1.62 Million
Q1 2024 Apr 30, 2024	BUY	$212.02 - $267.71 $699,666 - $883,442	3,300 Added 85.49%	7,160 $1.54 Million
Q4 2023 Feb 13, 2024	BUY	$222.59 - $267.94 $171,839 - $206,849	772 Added 25.0%	3,860 $998,000
Q3 2023 Nov 06, 2023	SELL	$253.3 - $285.89 $185,415 - $209,271	-732 Reduced 19.16%	3,088 $793,000
Q1 2023 May 03, 2023	BUY	$256.56 - $292.34 $282,216 - $321,574	1,100 Added 40.44%	3,820 $1.06 Million
Q4 2022 Feb 02, 2023	BUY	$252.44 - $306.72 $686,636 - $834,278	2,720 New	2,720 $753,000
Q2 2022 Jul 28, 2022	SELL	$187.54 - $223.02 $2.51 Million - $2.99 Million	-13,400 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$193.77 - $244.14 $2.6 Million - $3.27 Million	13,400 New	13,400 $2.82 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management B.V. with notifications on news.